Apogee Therapeutics (NASDAQ:APGE) Earns Outperform Rating from Wedbush
Wedbush reaffirmed their outperform rating on shares of Apogee Therapeutics (NASDAQ:APGE – Free Report) in a report released on Monday, RTT News reports. Wedbush currently has a $40.00 target price on the stock. Wedbush also issued estimates for Apogee Therapeutics’ Q4 2023 earnings at ($0.44) EPS, FY2023 earnings at ($2.92) EPS, Q2 2024 earnings at […]
More Stories
Bank of America Co. (NYSE:BAC) Shares Purchased by Trust Co of the South
Trust Co of the South raised its position in Bank of America Co. (NYSE:BAC – Free Report) by 2.7% in...
Trust Co of the South Lowers Stock Holdings in Waste Management, Inc. (NYSE:WM)
Trust Co of the South trimmed its position in Waste Management, Inc. (NYSE:WM – Free Report) by 10.5% during the...
Trust Co of the South Reduces Stock Holdings in Danaher Co. (NYSE:DHR)
Trust Co of the South trimmed its stake in Danaher Co. (NYSE:DHR – Free Report) by 15.8% in the 4th...
First Citizens BancShares, Inc. (NASDAQ:FCNCA) Shares Purchased by Trust Co of the South
Trust Co of the South lifted its position in shares of First Citizens BancShares, Inc. (NASDAQ:FCNCA – Free Report) by...
Trust Co of the South Sells 93 Shares of Duke Energy Co. (NYSE:DUK)
Trust Co of the South trimmed its holdings in shares of Duke Energy Co. (NYSE:DUK – Free Report) by 0.9%...
Trust Co of the South Buys 89 Shares of iShares Core S&P 500 ETF (NYSEARCA:IVV)
Trust Co of the South boosted its stake in shares of iShares Core S&P 500 ETF (NYSEARCA:IVV – Free Report)...